ATE415161T1 - Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen - Google Patents

Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen

Info

Publication number
ATE415161T1
ATE415161T1 AT02719776T AT02719776T ATE415161T1 AT E415161 T1 ATE415161 T1 AT E415161T1 AT 02719776 T AT02719776 T AT 02719776T AT 02719776 T AT02719776 T AT 02719776T AT E415161 T1 ATE415161 T1 AT E415161T1
Authority
AT
Austria
Prior art keywords
antestrogens
combination
transferase inhibitor
protein transferase
farnesyl protein
Prior art date
Application number
AT02719776T
Other languages
English (en)
Inventor
David End
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE415161T1 publication Critical patent/ATE415161T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Detergent Compositions (AREA)
AT02719776T 2001-02-15 2002-02-06 Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen ATE415161T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26883901P 2001-02-15 2001-02-15

Publications (1)

Publication Number Publication Date
ATE415161T1 true ATE415161T1 (de) 2008-12-15

Family

ID=23024710

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02719776T ATE415161T1 (de) 2001-02-15 2002-02-06 Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen

Country Status (7)

Country Link
US (4) US20040110769A1 (de)
EP (1) EP1365763B1 (de)
JP (2) JP4969016B2 (de)
AT (1) ATE415161T1 (de)
DE (1) DE60230017D1 (de)
ES (1) ES2318000T3 (de)
WO (1) WO2002064142A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064142A1 (en) * 2001-02-15 2002-08-22 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with antiestrogen agents
AU2003272964A1 (en) * 2002-10-09 2004-05-04 Kyowa Hakko Kogyo Co., Ltd. Remedy for hormone-dependent cancer
US7838531B2 (en) * 2002-10-18 2010-11-23 The United States Of America As Represented By The Department Of Health And Human Services Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
WO2004035753A2 (en) 2002-10-18 2004-04-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lmna gene and its involvement in hutchinson-gilford progeria syndrome (hgps) and arteriosclerosis
BRPI0416316A (pt) * 2003-11-06 2007-01-09 Schering Corp combinação de um inibidor da farnesil transferase com um agente anti-hormonal para o tratamento de cáncer de mama
AU2006331542A1 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
HK1213887A1 (zh) 2012-10-16 2016-07-15 Janssen Pharmaceutica N.V. RORγt的苯基连接的喹啉基调节剂
WO2014062655A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
CA2927182A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Quinolinyl modulators of ror.gamma.t
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
CA2926339A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of roryt
PL3137078T3 (pl) * 2014-05-01 2019-08-30 Eiger Biopharmaceuticals, Inc. Leczenie zakażenia wirusem zapalenia wątroby typu delta
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
US10471055B2 (en) 2015-08-17 2019-11-12 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
HRP20210544T1 (hr) 2016-11-03 2021-08-20 Kura Oncology, Inc. Inhibitori farneziltransferaze za uporabu u liječenju raka

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69635966T2 (de) * 1995-12-08 2006-11-30 Janssen Pharmaceutica N.V. (Imidazol-5-yl)Methyl-2-Chinolinonderivate als Farnesyl Protein transferase Inhibitoren
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
SK146199A3 (en) * 1997-04-25 2000-06-12 Janssen Pharmaceutica Nv Farnesyltransferase inhibiting quinazolinones
CN1275911A (zh) * 1997-08-15 2000-12-06 杜克大学 一种预防或治疗雌激素依赖性疾病及失调的方法
PT1041985E (pt) * 1997-12-22 2006-07-31 Schering Corp Combinacao de compostos benzociclo-heptapiridina e farmacos antineoplasicos para tratar doencas proliferativas
DE19826213A1 (de) * 1998-06-09 1999-12-16 Schering Ag Neue Antiestrogene, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
AU1230100A (en) * 1998-10-29 2000-05-22 Merck & Co., Inc. A method of treating endometriosis
PT1140935E (pt) * 1998-12-23 2003-10-31 Janssen Pharmaceutica Nv Derivados da quinolina 1,2-ciclizada
PT1255537E (pt) * 2000-02-04 2006-09-29 Janssen Pharmaceutica Nv Inibidores da proteina farnesil transferase para tratar cancro da mama
JP2003523381A (ja) * 2000-02-24 2003-08-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 投与レジメン
WO2002024683A1 (en) * 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derivatives
WO2002064142A1 (en) * 2001-02-15 2002-08-22 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with antiestrogen agents

Also Published As

Publication number Publication date
WO2002064142A1 (en) 2002-08-22
JP2010047589A (ja) 2010-03-04
US20120108634A1 (en) 2012-05-03
JP4865027B2 (ja) 2012-02-01
JP4969016B2 (ja) 2012-07-04
US20040110769A1 (en) 2004-06-10
US20110105557A1 (en) 2011-05-05
US20090023776A1 (en) 2009-01-22
EP1365763A1 (de) 2003-12-03
JP2004517960A (ja) 2004-06-17
EP1365763B1 (de) 2008-11-26
DE60230017D1 (de) 2009-01-08
ES2318000T3 (es) 2009-05-01

Similar Documents

Publication Publication Date Title
DE60230017D1 (de) Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
WO2001064226A3 (en) Farnesyl protein transferase inhibitor combinations with platinum compounds
WO2001064246A3 (en) Farnesyl protein transferase inhibitor combinations with an her2 antibody
WO2001064194A3 (en) Farnesyl protein transferase inhibitor combinations with camptothecin compounds
WO2001064252A3 (en) Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
NZ514628A (en) Use of inhibitors for inducing cancer cell death and tumor regression
ATE316785T1 (de) Jak-3 hemmer zur behandlung von allergischen störungen
JO2305B1 (en) Gels extracted from wood
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
ATE415979T1 (de) Behandlung mit anti-erbb2 antikörpern
ATE355079T1 (de) Behandlung von prostata-krebs mit anti-erbb2 antikörpern
MY133403A (en) Tetracycline derivatives and methods of use thereof
BR0208373A (pt) Inibidores da tirosina cinase
MXPA05006629A (es) Formas de dosificacion que contienen un inhibidor de bomba de protones, un nsaid y un amortiguador.
MXPA02007099A (es) Compuestos de tiazola, imidazola y oxazola y tratamientos de desordenes asociados con la maduracion de la proteina.
NO20044996L (no) Furylforbindelser
DE602004018780D1 (de) Inhibitoren von thienopyridin- und furopyridinkinase
WO2001064218A3 (en) Farnesyl protein transferase inhibitor combinations
WO2001064199A3 (en) Farnesyl protein transferase inhibitor combinations with taxane compounds
WO2001064217A3 (en) Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
ATE253062T1 (de) 4- und 5-alkynyloxindole sowie 4- und 5- alkenyloxindole
EA200400235A1 (ru) Комбинированная терапия для лечения рака
WO2001064198A3 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
BR0308606A (pt) Derivados de hemiasterlina e usos destes
WO2001064195A3 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties